Christopher Lowe
UCB
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher Lowe.
Bioorganic & Medicinal Chemistry Letters | 2001
Matt Barnes; Nicola Cooper; Richard John Davenport; Hazel Joan Dyke; Fiona P. Galleway; Frances Celia Anne Galvin; Lewis Gowers; Alan Findlay Haughan; Christopher Lowe; Johannes W.G. Meissner; John Gary Montana; Trevor Morgan; C.Louise Picken; Robert John Watson
The synthesis of a novel series of guanine analogues is reported. The compounds have been assessed in vitro and some analogues have been found to be inhibitors of phosphodiesterase type 7 (PDE7).
Bioorganic & Medicinal Chemistry Letters | 2002
M. Motasim Billah; Nicola Cooper; Francis M. Cuss; Richard John Davenport; Hazel Joan Dyke; Robert W. Egan; Ashit K. Ganguly; Lewis Gowers; Duncan Hannah; Alan Findlay Haughan; Hannah Jayne Kendall; Christopher Lowe; Michael Minnicozzi; John Gary Montana; Robert J. Naylor; Janet Oxford; Joanna C. Peake; John J. Piwinski; Karen Ann Runcie; Verity Margaret Sabin; Andrew Sharpe; Neng-Yang Shih; Julie B.H. Warneck
The syntheses and pharmacological profiles of some 2-trifluoromethyl-8-methoxyquinoline-5-carboxamides are described. SCH351591 is a potent selective inhibitor of phosphodiesterase type 4 (PDE4).
Bioorganic & Medicinal Chemistry Letters | 2002
M. Motasim Billah; George M. Buckley; Nicola Cooper; Hazel Joan Dyke; Robert W. Egan; Ashit K. Ganguly; Lewis Gowers; Alan Findlay Haughan; Hannah Jayne Kendall; Christopher Lowe; Michael Minnicozzi; John Gary Montana; Janet Oxford; Joanna C. Peake; C.Louise Picken; John J. Piwinski; Robert J. Naylor; Verity Margaret Sabin; Neng-Yang Shih; Julie B.H. Warneck
The synthesis and pharmacological profile of a novel series of 2-substituted 8-methoxyquinolines is described. The 2-trifluoromethyl compound was found to be a potent inhibitor of phosphodiesterase type 4 (PDE4).
Bioorganic & Medicinal Chemistry Letters | 1998
John Gary Montana; George M. Buckley; Nicola Cooper; Hazel Joan Dyke; Lewis Gowers; Joanna P Gregory; Paul G. Hellewell; Hannah Jayne Kendall; Christopher Lowe; Robert James Maxey; Jadwiga M. Miotla; Robert J. Naylor; Karen Ann Runcie; B. R. Tuladhar; Julie B.H. Warneck
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly observed with PDE4 inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2008
Alistair H. Bingham; Richard John Davenport; Richard Fosbeary; Lewis Gowers; Roland L. Knight; Christopher Lowe; David Alan Owen; David M. Parry; Will R. Pitt
The synthesis and structure-activity relationship of a novel series of aminopyrimidines are exemplified. Results of key compounds from within this series in the E-selectin reporter cell assay are also reported.
Bioorganic & Medicinal Chemistry Letters | 2002
George M. Buckley; Nicola Cooper; Richard John Davenport; Hazel Joan Dyke; Fiona P. Galleway; Lewis Gowers; Alan Findlay Haughan; Hannah Jayne Kendall; Christopher Lowe; John Gary Montana; Janet Oxford; Joanna C. Peake; C.Louise Picken; Marianna Dilani Richard; Verity Margaret Sabin; Andrew Sharpe; Julie B.H. Warneck
The synthesis and pharmacological profile of a novel series of 7-methoxy-furo[2,3-c]pyridine-4-carboxamides is described. Some of these compounds were found to be potent inhibitors of phosphodiesterase type 4 (PDE4).
Bioorganic & Medicinal Chemistry Letters | 2000
George M. Buckley; Nicola Cooper; Hazel Joan Dyke; Fiona P. Galleway; Lewis Gowers; Joanna C Gregory; Duncan R Hannah; Alan Findlay Haughan; Paul G. Hellewell; Hannah Jayne Kendall; Christopher Lowe; Robert James Maxey; John Gary Montana; Robert J. Naylor; C.Louise Picken; Karen Ann Runcie; Verity Margaret Sabin; Bishwa R Tuladhar; Julie B.H. Warneck
The synthesis and pharmacological profile of a novel series of 7-methoxybenzofuran-4-carboxamides is described. Some of these compounds were found to be potent inhibitors of phosphodiesterase type 4 (PDE4).
Bioorganic & Medicinal Chemistry Letters | 2002
George M. Buckley; Nicola Cooper; Hazel Joan Dyke; Fiona P. Galleway; Lewis Gowers; Alan Findlay Haughan; Hannah Jayne Kendall; Christopher Lowe; Robert James Maxey; John Gary Montana; Robert J. Naylor; Janet Oxford; Joanna C. Peake; C.Louise Picken; Karen Ann Runcie; Verity Margaret Sabin; Andrew Sharpe; Julie B.H. Warneck
A series of bicyclic heteroaryl ring systems was considered as a replacement for the 3-cyclopentyloxy-4-methoxyphenyl moiety in rolipram resulting in the discovery of 8-methoxyquinoline-5-carboxamides as potent inhibitors of phosphodiesterase type 4 (PDE4).
Archive | 1996
John Gary Montana; Hazel Joan Dyke; Robert James Maxey; Christopher Lowe
Bioorganic & Medicinal Chemistry Letters | 2007
Mahbub Alam; Rebekah Beevers; Tom Ceska; Richard John Davenport; Karen M. Dickson; Mara Fortunato; Lewis Gowers; Alan Findlay Haughan; Lynwen James; Mark W. Jones; Natasha Kinsella; Christopher Lowe; Johannes W.G. Meissner; Anne-Lise Nicolas; Benjamin Perry; David J. Phillips; William R. Pitt; Adam Samuel Platt; Andrew J. Ratcliffe; Andrew Sharpe; Laura Jane Tait